Peter Ciszewski, CheckRare
Rare Disease Discussions
News and clinical perspective including CME programs focused on rare diseases. CheckRare focuses on rare and neglected diseases.
Vizitează neapărat site-ul podcastului și susține-i creatorul: www.checkrare.com
Autor
Peter Ciszewski, CheckRare
Categorie
Site-ul podcastului
Cel mai nou episod
19 nov. 2026
Unde asculți?
Podcasturi în aplicație Replaio Radio În curândPodcasturile ajung în curând în aplicație. Instaleaz-o acum și fii primul care descoperă o abordare complet nouă a podcasturilor
Episoade
International Rett Syndrome Foundation Works to Advance Research and Support Families 19.11.2026 39:00
Laura Hameed, Chief Executive Officer, and Dominique Pichard, MD, MS, Chief Scientific and Medical Officer of the International Rett Syndrome Foundation (IRSF) , discuss the changing treatment landscape for Rett syndrome and the organization’s commitment to supporting patients and their families. Rare Discussions is produced by CheckRare , the leading multimedia platform dedicated to advancing ed...
Three-Year Study Finds Burosumab Improves Symptoms in Adults With X-Linked Hypophosphatemia 19.11.2026 8:09
Steven Ing, MD, Professor of Clinical Medicine in the Division of Endocrinology, Diabetes and Metabolism at The Ohio State University Wexner Medical Center, discusses three-year real-world findings from an interim analysis of the XLH Disease Monitoring Program (DMP) comparing burosumab with conventional therapy in adults with X-linked hypophosphatemia (XLH). Rare Discussions is produced by CheckRa...
Trutakna Meets All Prespecified Endpoints in Phase 3 ORIGIN 3 Trial in IgA Nephropathy 17.11.2026 13:02
Positive final efficacy results from the phase 3 ORIGIN 3 trial, evaluating Trutakna (atacicept) in adults with primary IgA nephropathy (IgAN) at risk of disease progression. Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, discusses the findings Rare Discussions is produced by CheckRare , the leading multimedia platform dedicated to advancing education, awareness, and innovation across...
Analysis Finds Ralinepag Reduces Clinical Worsening Across PAH Risk Profiles 16.11.2026 7:51
A poster analysis of the phase 3 ADVANCE OUTCOMES trial, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that oral ralinepag reduced clinical worsening across different baseline risk profiles in patients with pulmonary arterial hypertension (PAH). Jean Elwing, MD, FCCP, Professor of Clinical Internal Medicine at the University of Cincinnati, discusses the findings and their i...
The Need for Earlier Pulmonary Hypertension Screening in Interstitial Lung Disease 13.11.2026 11:58
Parth Rali, MD, MBBS, FCCP, pulmonologist at Temple Health, discusses interim findings from the PHINDER study evaluating pulmonary hypertension (PH) screening strategies in patients with interstitial lung disease (ILD). Rare Discussions is produced by CheckRare , the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community. Explore a...
UCB Study Highlights the Burden of Ocular Myasthenia Gravis 12.11.2026 11:15
Biopharmaceutical company UCB recently shared findings from a mixed-methods study examining the experiences and unmet needs of people living with ocular myasthenia gravis (oMG). The findings were presented at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session. Anna Kole, Global...
Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPF 11.11.2026 9:14
A post-hoc analysis of the phase 3 TETON-2 study, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that inhaled treprostinil significantly reduced multiple disease progression events in patients with idiopathic pulmonary fibrosis (IPF). Steven Nathan, MD, MBBCh, FCCP, Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital, discusses the fin...
Phase 3 OASIS Study Shows Promise of Oral Olorofim for Invasive Aspergillosis 10.11.2026 7:42
Johan Maertens, MD, PhD, Professor of Hematology at University Hospitals Leuven (UZ Leuven) in Belgium and Principal Investigator of the OASIS study, discusses positive phase 3 trial results evaluating oral olorofim in patients with invasive aspergillosis. Rare Discussions is produced by CheckRare , the leading multimedia platform dedicated to advancing education, awareness, and innovation across...
Garetosmab Demonstrates Sustained Efficacy in Adults With Fibrodysplasia Ossificans Progressiva 09.11.2026 5:10
Richard Keen, MD, PhD, Director of the Metabolic Bone Disease Centre at the Royal National Orthopaedic Hospital in London and global principal investigator of the OPTIMA trial, discusses positive 84-week results from the phase 3 OPTIMA trial extension, evaluating Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP). Rare Discussions is produced by CheckRare , the le...
C3G and the Pediatric VALIANT Study 06.11.2026 10:49
Bradley Dixon, MD, a pediatric nephrologist, and Chief of Pediatric Nephrology, Children’s Hospital of Colorado, and Professor of Pediatrics, University of Colorado School of Medicine, discussed complement 3 glomerulopathy (C3G) with CheckRare. Complement 3 glomerulopathy (or C3G) is a form of membranoproliferative glomerulonephritis, an inflammatory process. It occurs when the complement system,...
A Family’s Journey with Prader-Willi Syndrome 06.11.2026 10:22
Maria Picone, co-founder and CEO of the TREND Community, and mother of a 14-year-old with Prader-Willi syndrome (PWS), discusses her family’s journey with PWS, including why more research and better data are so important. Rare Discussions is produced by CheckRare , the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community. Explore...
Molecular Changes Associated With Teprotumumab Treatment in Thyroid Eye Disease 04.11.2026 6:35
Sarah Cheng, MD, PhD, a clinical oculoplastic fellow at the University of California, San Diego, discusses findings from an exploratory study examining the biological changes in orbital tissue associated with Tepezza (teprotumumab-trbw) treatment. The findings were presented at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans, Louisiana. Rare Discussions is produced...
Mirum's Livmarli Achieves Primary Endpoint in Phase 3 EXPAND Study 03.11.2026 18:45
Mirum Pharmaceuticals recently announced positive topline results from its phase 3 EXPAND study, evaluating Livmarli (maralixibat) for cholestatic pruritus in patients six months and older with ultra-rare cholestatic liver diseases. Jennifer Vittorio, MD, an EXPAND investigator, an Associate Professor of Pediatrics, and the Medical Director of Pediatric Liver Transplantation at NYU Langone Health,...
How Bispecific Antibodies Are Changing Multiple Myeloma Treatment 02.11.2026 12:05
Nisha Joseph, MD, Associate Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, discusses how bispecific antibodies are changing multiple myeloma treatment. Multiple myeloma is a rare cancer of the plasma cells and the most common type of plasma tumor. Plasma cells are white blood cells that make antibodies to protect against infection. In mu...
Miv-cel Shows Durable Results in Stiff Person Syndrome and Myasthenia Gravis 30.10.2026 15:53
Naji Gehchan, MD, MBA, Chief Medical and Development Officer at Kyverna Therapeutics, discusses one-year data showing sustained benefits of KYV-101 (mivocabtagene autoleucel ; Miv-cel) in stiff person syndrome (SPS), along with longer-term follow-up data in generalized myasthenia gravis (gMG). SPS and gMG are rare neurological and neuromuscular disorders: SPS: SPS is a rare, progressive neurologic...
Z-Basivarsen Shows Functional Improvements in One-Year Data for Myotonic Dystrophy Type 1 27.10.2026 9:02
Laurie Gutmann, MD, professor of neurology at Indiana University, discusses data showing functional improvements with zeleciment basivarsen (z-basivarsen; DYNE-101) in patients with myotonic dystrophy type 1. Myotonic dystrophy type 1 (DM1), also known as Steinert disease, is a rare, inherited type of muscular dystrophy. Its estimated worldwide prevalence is approximately 1 in 20,000 people . DM1...
FDA Approves Gazyva to Reduce Relapse Risk in Patients With Idiopathic Nephrotic Syndrome 26.10.2026 10:37
Andrea Callaway, president and founder of The Nephrotic Syndrome Foundation, discusses the FDA approval of Gazyva (obinutuzumab) for idiopathic nephrotic syndrome (INS) and what the approval means for affected families. INS is a rare autoimmune kidney disease that’s commonly diagnosed in early childhood. It causes the kidneys to leak large amounts of protein into the urine, which can result in we...
Efficacy of Vosoritide to Treat Hypochondroplasia 23.10.2026 12:24
Andrew Dauber, MD, MMsc, Chief of Endocrinology at Children’s National, discusses the efficacy of vosoritide to treat persons with hypochondroplasia. Hypochondroplasia is a rare skeletal disease characterized by very short stature, similar to achondroplasia, but with milder features. People with hypochondroplasia usually have very short stature, large head, accentuated lordosis, short arms and leg...
Efficacy of Infigratinib on Achondroplasia 21.10.2026 15:59
Daniela Rogoff, MD, PhD, Chief Medical Officer, Skeletal Dysplasia of BridgeBio, discusses the efficacy of infigratinib to treat persons with achondroplasia. Achondroplasia is a disorder of bone growth that prevents the changing of cartilage to bone, particularly in the long bones. It is characterized by dwarfism, limited range of motion at the elbows, macrocephaly, and small fingers. Achondroplas...
Breakthrough Therapy Designation to Cimzia for Antiphospholipid Syndrome 19.10.2026 16:47
Jane Salmon, MD, Professor of Medicine at Weill Cornell Medical College, discusses antiphospholipid syndrome (APS), its impact on pregnancy, and emerging research into Cimzia (certolizumab pegol) as a potential approach to preventing serious pregnancy complications. APS is an autoimmune condition characterized by an increased risk of thrombosis and serious pregnancy complications (e.g., preeclamp...
FDA Approves Gazyva for Idiopathic Nephrotic Syndrome, Offering a New Treatment Option 16.10.2026 8:50
Keisha L. Gibson, MD, MPH, pediatric nephrologist at the UNC School of Medicine, discusses the approval of Gazyva (obinutuzumab) for patients with childhood-onset idiopathic nephrotic syndrome (INS). INS is a rare, autoimmune kidney disease that is often managed by corticosteroids and/or mycophenolate mofetil. The disease and treatment however, is characterized by unpredictable relapses that cause...
New Stem Cell Method Could Advance Research Into Spinal Muscular Atrophy 16.10.2026 13:26
Kyle Loh, PhD, Associate Professor at Stanford Medicine, discusses research that could help scientists better understand spinal muscular atrophy (SMA) by generating new motor neurons from human hindbrain cells in the laboratory. SMA is a genetic neuromuscular disorder characterized by the loss of motor neurons, causing progressive muscle weakness and loss of movement due to atrophy. SMA mainly...
Revumenib + Chemotherapy in Newly Diagnosed AML With NPM1 Mutation: Phase 3 REVEAL-ND Study 15.10.2026 5:13
My name is Dr. Joshua Zeidner, and I’m a Professor of Medicine and Chief of Leukemia Research at the University of North Carolina Lineberger Cancer Center. I’m here today to raise awareness around an active global, phase 3, double-blind trial evaluating a combination regimen for participants with a specific type of acute myeloid leukemia or AML. Disclaimer: This material is intended for healthcare...
Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer 15.10.2026 3:30
Jorge Nieva, MD, Associate Professor at the Keck School of Medicine, discusses new analyses from the TRUST studies evaluating taletrectinib in patients with ROS1-positive non-small cell lung cancer (NSCLC). ROS1-positive NSCLC is a rare molecular subtype of non-small cell lung cancer in which changes involving the ROS1 gene can drive tumor growth. Identifying ROS1-positive disease is important bec...
Plasma Proteomics May Predict Disease Manifestations in ALS 14.10.2026 10:02
Michael Benatar, MD, PhD, Department of Neurology and ALS Center, University of Miami Miller School of Medicine, discusses the use of plasma proteomics in predicting clinical manifestations of amyotrophic lateral sclerosis (ALS). ALS is a rare motor neuron disease characterized by problems with muscle control and movement. Early symptoms may include muscle twitching, cramping, stiffness, or weakne...
Podcasturi asemănătoare
Replaio nu este editorul podcasturilor; numele emisiunilor, coperțile și materialul audio aparțin autorilor lor și sunt distribuite prin fluxuri RSS publice